In Vivo Imaging of Endogenous Pancreatic β-Cell Mass in Healthy and Type 1 Diabetic Subjects Using 18F-Fluoropropyl-Dihydrotetrabenazine and PET

@article{Normandin2012InVI,
  title={In Vivo Imaging of Endogenous Pancreatic $\beta$-Cell Mass in Healthy and Type 1 Diabetic Subjects Using 18F-Fluoropropyl-Dihydrotetrabenazine and PET},
  author={Marc D. Normandin and Kitt Falk Petersen and Yu-Shin Ding and Shu-Fei Lin and Sarita S. Naik and Krista Fowles and Daniel M. Skovronsky and Kevan C. Herold and Timothy J. McCarthy and Roberto A. Calle and Richard E. Carson and Judith L. Treadway and Gary W. Cline},
  journal={The Journal of Nuclear Medicine},
  year={2012},
  volume={53},
  pages={908 - 916}
}
The ability to noninvasively measure endogenous pancreatic β-cell mass (BCM) would accelerate research on the pathophysiology of diabetes and revolutionize the preclinical development of new treatments, the clinical assessment of therapeutic efficacy, and the early diagnosis and subsequent monitoring of disease progression. The vesicular monoamine transporter type 2 (VMAT2) is coexpressed with insulin in β-cells and represents a promising target for BCM imaging. Methods: We evaluated the VMAT2… 

Figures and Tables from this paper

Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO

11C-(+)-PHNO is a potential marker of BCM, with 2:1 binding of D3 receptors over D2 receptors, and in vitro and in vivo studies to establish D2/D3 receptor specificity to β-cells are warranted.

Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin

These studies indicate that 111In-labelled exendin may be suitable for non-invasive quantification of BCM in vivo in a rodent model of beta cell loss and in patients with type 1 diabetes and healthy individuals.

Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging

The observed correlations of VMAT2 density in the pancreas and Pancreas regions with years since diagnosis of type 2 diabetes, glycaemic control and beta cell function suggest that loss of BCM contributes to deficient insulin secretion in humans with type 2abetes.

Validation of 111In-Exendin SPECT for the Determination of the β-Cell Mass in BioBreeding Diabetes-Prone Rats

Results indicate that 111In-exendin is a promising tracer to determine the BCM during the development of T1D, irrespective of the degree of insulitis.

Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes

This was the first human study of [18F]FP-(−)-DTBZ and use of scaled spleen VT values for VND is a suitable method for quantification of VMAT2 in the pancreas.

Beta-Cell Imaging: Call for Evidence-Based and Scientific Approach

The assertion that BCM can be accurately quantified by tetrabenazine derived β-cell-specific radiotracers as density per unit volume of pancreatic tissue is not justifiable at this time.

First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [18F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas

18F-Ex4 PET/CT demonstrated the safety and utility for non-invasive visualization of the pancreas in healthy male subjects and is promising for clinical PET imaging targeting pancreatic β cells.

Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond

Recent advances in non-invasive in vivo β-cell imaging for BCM evaluation in the field of diabetes are focused on, in particular, the exendin-based GLP-1R-targeted nuclear medicine techniques.
...

References

SHOWING 1-10 OF 41 REFERENCES

In Vivo Imaging of β-Cell Mass in Rats Using 18F-FP-(+)-DTBZ: A Potential PET Ligand for Studying Diabetes Mellitus

The preliminary data obtained with 18F-FP-(+)-DTBZ suggest that this fluorinated derivative of DTBZ shows good Pancreas specificity and has the potential to be useful for quantitative measurement of VMAT2 binding sites reflecting BCM in the pancreas.

Pancreatic Beta Cell Mass PET Imaging and Quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in Rodent Models of Diabetes

PET imaging with [18F]FP-(+)-DTBZ provides a noninvasive means to quantify insulin-positive BCM and may prove valuable as a diagnostic tool in assessing treatments to maintain or restore BCM.

Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model.

It is suggested that PET-based quantitation of VMAT2 receptors provides a noninvasive measurement of BCM that could be used to study the pathogenesis of diabetes and to monitor therapeutic interventions.

11C-Dihydrotetrabenazine PET of the Pancreas in Subjects with Long-Standing Type 1 Diabetes and in Healthy Controls

The results suggest that 11C-dihydrotetrabenazine PET allows quantification of VMAT2 binding in the human pancreas, however, BPND and functional binding capacity appear to overestimate β-cell mass given the near-complete depletion of β- cell mass in long-standing type 1 diabetes.

Visualizing pancreatic β-cell mass with [11C]DTBZ

VMAT2 gene expression and function as it applies to imaging β-cell mass

Much of what is understood about the regulation of VMAT2 is summarized and questions whose answers may help in understanding what measurements of VMat2 density mean in the context of diabetes are identified.

Assessment of Islet Specificity of Dihydrotetrabenazine Radiotracer Binding in Rat Pancreas and Human Pancreas

It is suggested that the reduction in pancreatic 11C-DTBZ binding observed in type 1 diabetes is not specific for the loss of β-cell mass and is mainly due to nonspecific binding in the exocrine pancreas.

VMAT2 gene expression and function as it applies to imaging beta-cell mass.

Much of what is understood about the regulation of VMAT2 is summarized and questions whose answers may help in understanding what measurements of VMat2 density mean in the context of diabetes are identified.

Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival

It is shown that islet graft survival could be assessed for 1 month in diabetic NOD mice using quantitative in vivo PET imaging technology, the PET signal reflecting insulin secretory capacity of transplanted islets, and expression of the gene encoding viral interleukin-10, was measurable in real time with PET scanning.